Learn about Research & Clinical Trials

Autologous Bronchial Basal Cells Transplantation for Treatment of CRD Including COPD, BE and PF

Study Purpose

Chronic respiratory diseases including chronic obstructive pulmonary disease (COPD), bronchiectasis (BE) or pulmonary fibrosis (PF) are usually not curable with damaged pulmonary structure and function. Bronchial basal cells are proved to regenerate bronchus and alveoli to repair the pulmonary injuries. In this study, we intend to perform an open, single-armed phase I clinical trial by transplantation of autologous bronchial basal cells on patients suffered from COPD, BE or PF. During the treatment, autologous bronchial basal cells, which were isolated from fiberoptic bronchoscopy and expanded in vitro, will be injected directly into lesions by fiberoptic bronchoscopy after careful characterization. In the following 6 months, the safety and efficacy of the treatment will be monitored by measuring the key clinical indicators.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Diagnosed with COPD, BE or PF according to the guideline; - Clinically stable for more than 4 weeks; - Tolerant to fiberoptic bronchoscopy test; - Written informed consent signed.

Exclusion Criteria:

  • - Pregnant or lactating women; - Patients positive for syphilis, HIV; - Patients with malignant tumor; - Patients with serious significant pulmonary infection and need anti-infection treatment; - Patients with serious heart disease(NYHA class Ⅲ-Ⅳ); - Patients with a history of abusing alcohol and illicit drug; - Patients participated in other clinical trials in the past 3 months; - Patients assessed as inappropriate to participate in this clinical trial by investigators.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03153800
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Early Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Regend Therapeutics
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry, Other
Overall Status Recruiting
Countries China
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Chronic Respiratory Disease
Study Website: View Trial Website
Arms & Interventions

Arms

Experimental: Bronchial basal cells

Interventions

Biological: - bronchial basal cells

Transplantation of autologous bronchial basal cells by fiberoptic bronchoscopy.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Suzhou, Jiang Su, China

Status

Recruiting

Address

The First Affiliated Hopsital of Soochow University

Suzhou, Jiang Su, 215006

Site Contact

Jianan Huang, M.D.

huang_jian_an@163.com

086-400-882-1090